SynthesisFrontiers in oncology2025

Efficacy and safety of PARP inhibitors monotherapy or combination therapy with anti-angiogenics in ovarian cancer: a network meta-analysis.

Yuan Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.